Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZO GANTANOL vs AZO GANTRISIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.
Urinary tract infections (UTIs) when sulfonamide therapy is indicated (FDA),Pain relief of urinary tract irritation (phenazopyridine component)
Urinary tract infections,Pain relief associated with lower urinary tract irritation,Pyelonephritis
AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.
AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.
Sulfamethoxazole terminal half-life: 9-12 hours in adults with normal renal function (Cr Cl >80 m L/min); prolonged to 20-50 hours in CKD (Cr Cl <30 m L/min); phenazopyridine half-life: 9-11 hours
Sulfamethoxazole: 9-12 hours (adults with normal renal function), prolonged to 20-50 hours in renal impairment; trimethoprim component: 8-11 hours. Clinical context: dosing interval adjusted based on Cr Cl.
Sulfamethoxazole is primarily metabolized by N-acetylation in the liver (N-acetyltransferase 2); phenazopyridine is metabolized in the liver via glucuronidation and sulfation.
Sulfamethoxazole is metabolized primarily via N-acetylation in the liver; phenazopyridine undergoes hepatic metabolism.
Renal: 70% as sulfamethoxazole (30% acetylated), N5-acetylated metabolite accounts for 15%; fecal: 20% of dose excreted unchanged in bile; biliary: minor contribution (<5%)
Renal: 70-100% (sulfamethoxazole and metabolites; 15-30% as unchanged drug; remainder as acetylated and glucuronide conjugates). Biliary/fecal: <3%.
Sulfamethoxazole: 65-70% bound to albumin; phenazopyridine: >99% bound (mainly to albumin)
Sulfamethoxazole: 65-70% bound to albumin; trimethoprim: 40-45% bound to albumin.
Sulfamethoxazole: 0.21-0.28 L/kg (for a 70 kg person: ~15-20 L); phenazopyridine: 4.5-5.5 L/kg (extensive tissue binding, e.g., urinary tract)
Sulfamethoxazole: 0.2-0.3 L/kg (reflects distribution into extracellular fluid, not extensively tissue-bound); trimethoprim: 1-2 L/kg (higher due to lipophilicity, penetrates tissues including prostate and CSF). Clinical meaning: higher Vd of trimethoprim contributes to effective tissue concentrations.
Oral sulfamethoxazole: 85-95% (well absorbed); phenazopyridine: approximately 90% absorbed
Oral: 85-95% for both components (tablets); suspension: ~90%.
Sulfamethoxazole/Trimethoprim: Cr Cl >30 m L/min: no adjustment; Cr Cl 15-30 m L/min: reduce standard dose by 50% or extend interval to 24 hours; Cr Cl <15 m L/min: contraindicated. Phenazopyridine: contraindicated in renal impairment.
Cr Cl 50-80 m L/min: 1 tablet 3-4 times daily; Cr Cl 10-49 m L/min: 1 tablet 2-3 times daily; Cr Cl <10 m L/min: contraindicated.
Sulfamethoxazole/Trimethoprim: Child-Pugh A: no adjustment; Child-Pugh B: use with caution, no specific dose reduction; Child-Pugh C: contraindicated (risk of hepatotoxicity). Phenazopyridine: cautious use in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Sulfamethoxazole/Trimethoprim: 6-12 mg/kg/day of trimethoprim component divided every 12 hours; maximum 320 mg trimethoprim/day. Phenazopyridine: not recommended in children <12 years.
Children 6-12 years: 0.5-1.5 teaspoons (2.5-7.5 m L) of suspension (equivalent to 75-225 mg sulfisoxazole and 15-45 mg phenazopyridine) orally 4 times daily; children >12 years: adult dose.
Sulfamethoxazole/Trimethoprim: monitor renal function; reduce dose if Cr Cl <30 m L/min. Increased risk of hyperkalemia and sulfonamide-induced adverse effects. Phenazopyridine: cautious use due to potential renal impairment and CNS effects.
Initiate at lower doses (e.g., 1 tablet 3 times daily) and monitor for renal function and CNS side effects; contraindicated if Cr Cl <50 m L/min.
Sulfonamides, including sulfamethoxazole, may cause severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis.
Sulfonamides have been associated with severe reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Fatalities have occurred.
Risk of hypersensitivity reactions including SJS/TEN; blood dyscrasias (agranulocytosis, aplastic anemia); hepatotoxicity; renal impairment; photosensitivity; interference with urine glucose tests.
Risk of severe hypersensitivity reactions, blood dyscrasias, hepatotoxicity, and renal impairment. Use caution in patients with G6PD deficiency, hepatic impairment, or renal insufficiency. Phenazopyridine may cause orange-red discoloration of urine.
Hypersensitivity to sulfonamides or phenazopyridine; porphyria; severe renal impairment (Cr Cl <30 m L/min); G6PD deficiency; infants <2 months; pregnancy at term; lactation.
Hypersensitivity to sulfonamides or phenazopyridine; severe hepatic or renal impairment; porphyria; G6PD deficiency; pregnancy at term; lactation; children < 12 years (due to phenazopyridine component).
Avoid foods high in vitamin K (e.g., leafy greens) as sulfamethoxazole may potentiate warfarin effects. Maintain adequate fluid intake; dehydration increases crystalluria risk. No specific food avoidance required beyond general hydration.
Avoid acidic foods and beverages (e.g., citrus fruits, tomatoes, cola) as they may decrease the efficacy of sulfisoxazole by increasing urine acidity, which can reduce solubility and increase risk of crystalluria. Maintain adequate fluid intake; avoid alcohol. No other significant food interactions.
Phenazopyridine: No adequate studies; animal studies show no fetal harm but not conclusive. Sulfamethoxazole: First trimester – Possible increased risk of neural tube defects; second and third trimesters – Risk of kernicterus in neonate due to bilirubin displacement; avoid near term. Trimethoprim: First trimester – Folate antagonist, increased risk of neural tube defects and cardiovascular anomalies; second and third trimesters – No specific documented risks but theoretical folate antagonism.
Pregnancy Category D. First trimester: Associated with neural tube defects, cardiovascular anomalies, and oral clefts due to antifolate effect of trimethoprim. Second and third trimesters: Risk of kernicterus in newborn due to sulfonamide displacement of bilirubin from albumin, especially near term. Avoid use during pregnancy unless benefit outweighs risk.
Phenazopyridine: Excreted in breast milk; significance unknown; use caution. Sulfamethoxazole: Excreted in breast milk; M/P ratio ~0.2-0.3; risk of kernicterus in jaundiced or G6PD-deficient infants; avoid in nursing mothers of ill or premature infants. Trimethoprim: Excreted in breast milk; M/P ratio ~0.8-1.0; considered compatible by AAP but monitor infant for folate deficiency.
Sulfamethoxazole and trimethoprim are excreted into breast milk; M/P ratio not established. Avoid in nursing mothers with infants under 2 months of age due to risk of kernicterus. In older infants, caution if infant has G6PD deficiency or hyperbilirubinemia.
Pregnancy alters pharmacokinetics: Increased renal clearance may reduce sulfamethoxazole and trimethoprim levels; however, no dose adjustment is routinely recommended due to lack of data. Standard doses for urinary tract infection: one tablet (phenazopyridine 200 mg/sulfamethoxazole 400 mg/trimethoprim 80 mg) four times daily. Use lowest effective dose for shortest duration.
No standard dose adjustment recommended for pregnancy; however, caution due to increased volume of distribution and renal clearance. Monitor for therapeutic efficacy and toxicity. Consider folate supplementation (5 mg folic acid daily) to mitigate antifolate effects.
AZO GANTANOL combines phenazopyridine (a urinary analgesic) with sulfamethoxazole (a sulfonamide antibiotic). Monitor for sulfonamide hypersensitivity reactions (e.g., Stevens-Johnson syndrome). Phenazopyridine discolors urine orange-red; advise patients to avoid confusion with hematuria. Adjust sulfamethoxazole dose in renal impairment (Cr Cl <30 m L/min contraindicated).
AZO GANTRISIN combines phenazopyridine (urinary analgesic) and sulfisoxazole (sulfonamide antibiotic). Phenazopyridine imparts a red-orange color to urine and may stain contact lenses. Sulfisoxazole is contraindicated in infants <2 months due to risk of kernicterus. Use with caution in patients with G6PD deficiency, sulfonamide allergy, or renal impairment. Monitor for crystalluria; ensure adequate hydration. Avoid concurrent use with methenamine due to increased risk of crystalluria.
Take with a full glass of water to reduce risk of crystalluria.,Urine may turn orange-red; this is harmless and subsides after stopping the drug.,Complete full course even if symptoms improve; do not skip doses.,Avoid prolonged sun exposure; sulfonamides cause photosensitivity.,Report rash, fever, sore throat, or unusual bruising immediately.
Take this medication with a full glass of water and drink plenty of fluids throughout the day to prevent kidney stones.,Your urine may turn red-orange; this is harmless but may stain clothing or contact lenses.,Do not use for longer than 2 days unless directed by your doctor, as it only treats symptoms of UTI, not the infection.,Complete the full course of the sulfisoxazole component even if you feel better.,Avoid prolonged sun exposure; sulfonamides may cause photosensitivity. Use sunscreen.,Seek immediate medical attention if you develop skin rash, sore throat, fever, unusual bleeding, or bruising.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZO GANTANOL vs AZO GANTRISIN, answered by our medical review team.
AZO GANTANOL is a Sulfonamide Antibiotic that works by Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.. AZO GANTRISIN is a Sulfonamide Antibiotic that works by Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZO GANTANOL and AZO GANTRISIN depend on the specific clinical indication. These are both Sulfonamide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZO GANTANOL is: AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.. The standard adult dose of AZO GANTRISIN is: AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZO GANTANOL and AZO GANTRISIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZO GANTANOL is classified as Category C. Phenazopyridine: No adequate studies; animal studies show no fetal harm but not conclusive. Sulfamethoxazole: First trimester – Possible increased risk of neural tube defects; seco. AZO GANTRISIN is classified as Category C. Pregnancy Category D. First trimester: Associated with neural tube defects, cardiovascular anomalies, and oral clefts due to antifolate effect of trimethoprim. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.